Orphan disease drug developer PhaseBio Pharmaceuticals, which is commercialising research from Duke University, cut the price of its shares sharply pre-offering.
Cass Entrepreneurship Fund has returned to back a $3.9m funding round for Raremark, which is working on delivering precision medicine for patients suffering from rare diseases.
Qpex has raised $33m in series A funding from Stanford University Draper Fund after spinning out of the Medicines Company to develop drugs targeting superbugs.
